<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        456-212-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FANCATA 100MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CILOSTAZOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        67.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ADAMED Pharma S.A " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ADAMED Pharma S.A 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AC23
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Fancata belongs to a group of medicines called phosphodiesterase type 3 inhibitors. It has several actions which include widening of some blood vessels and reducing the clotting activity (clumping) of some blood cells called platelets inside your vessels.</p><p>&nbsp;</p><p>You have been prescribed Fancata for &quot;intermittent claudication&quot;. Intermittent claudication is the cramp-like pain in your legs when you walk and is caused by insufficient blood supply in your legs. Fancata can increase the distance you can walk without pain since it improves the blood circulation in your legs. Cilostazol is only recommended for patients whose symptoms have not improved sufficiently after making life-style modifications (such as stopping smoking and increasing exercise) and after other appropriate interventions. It is important that you continue the modifications you have made to your life-style whilst taking cilostazol.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Fancata</p><p>&middot; if you are allergic (hypersensitive) to cilostazol or any of the other ingredients of Fancata</p><p>&nbsp;</p><p>&middot; if you have the condition &quot;heart failure&quot;</p><p>&nbsp;</p><p>&middot; if you have persistent chest pain at rest, or have had a &ldquo;heart attack&rdquo; or any heart surgery in the last six months</p><p>&nbsp;</p><p>&middot; if you have now or previously suffered from blackouts due to heart disease, or any severe disturbances of the heart beats</p><p>&nbsp;</p><p>&middot; if you know that you have a condition which increases your risk of bleeding or bruising, such as:</p><p>&nbsp;</p><p>- active stomach ulcer(s)</p><p>&nbsp;</p><p>- stroke in the past six months</p><p>- problems with your eyes if you have diabetes</p><p>&nbsp;</p><p>- if your blood pressure is not well controlled</p><p>&nbsp;</p><p>&middot; if you are taking both acetylsalicylic acid and clopidogrel, or any combination of two or more medicines which can increase your risk of bleeding [ask your doctor or pharmacist if you are not sure]</p><p>&middot; if you have severe kidney disease or moderate or severe liver disease</p><p>&nbsp;</p><p>&middot; if you are pregnant</p><p>&nbsp;</p><p>Take special care with Fancata</p><p>&nbsp;</p><p>Before taking Fancata make sure your doctor knows:</p><p>&nbsp;</p><p>&middot; if you have a severe heart problem or any problems with your heart beat</p><p>&nbsp;</p><p>&middot; if you have problems with your blood pressure</p><p>&nbsp;</p><p>During treatment with Fancata make sure that:</p><p>&nbsp;</p><p>&middot; If you need to have surgery including having teeth removed, tell your doctor or dentist that you are taking Fancata</p><p>&nbsp;</p><p>&middot; If you experience easy bruising or bleeding, stop taking Fancata and tell your doctor</p><p>&nbsp;</p><p>Taking other medicines</p><p>&nbsp;</p><p>Before you start taking Fancata please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>&nbsp;</p><p>You should specifically inform your doctor if you take some medicines usually used to treat painful and/or inflammatory conditions of muscle or joints, or if you take medicines to reduce blood clotting. These medicines include:</p><p>&nbsp;</p><p>&middot; acetylsalicylic acid</p><p>&nbsp;</p><p>&middot; clopidogrel</p><p>&nbsp;</p><p>&middot; anticoagulant medicines (e.g. warfarin, dabigatran, rivaroxaban, apixaban or low molecular weight heparins)</p><p>&nbsp;</p><p>If you are taking such medicines with Fancata your doctor may perform some routine blood tests.</p><p>&nbsp;</p><p>Certain medicines may interfere with the effect of Fancata when taken together. They may either increase the side effects of Fancata or make Fancata less effective. Fancata may do the same to other medicines. Before you start taking Fancata, please tell your doctor if you are taking:</p><p>&nbsp;</p><p>&middot; erythromycin, clarithromycin or rifampicin (antibiotics)</p><p>&nbsp;</p><p>&middot; ketoconazole (to treat fungal infections)</p><p>&nbsp;</p><p>&middot; omeprazole (to treat excess acid in the stomach)</p><p>&nbsp;</p><p>&middot; diltiazem (to treat high blood pressure or chest pain)</p><p>&nbsp;</p><p>&middot; cisapride (to treat stomach disorders)</p><p>&nbsp;</p><p>&middot; lovastatin, simvastatin or atorvastatin (to treat high cholesterol in the blood)</p><p>&nbsp;</p><p>&middot; halofantrine (to treat malaria)</p><p>&nbsp;</p><p>&middot; pimozide (to treat mental illnesses)</p><p>&nbsp;</p><p>&middot; ergot derivatives (to treat migraine, e.g. ergotamine, dihydroergotamine)</p><p>&nbsp;</p><p>&middot; carbamazepine or phenytoin (to treat convulsions)</p><p>&nbsp;</p><p>&middot; St. John&rsquo;s wort (a herbal remedy)</p><p>&nbsp;</p><p>If you are not sure if this applies to your medicines ask your doctor or pharmacist.</p><p>&nbsp;</p><p>Before you start taking Fancata, please inform your doctor if you are taking medicines for high blood pressure because Fancata may have an additional lowering effect on your blood pressure. If your blood pressure falls too low, this could cause a fast heartbeat. These medicines include:</p><p>&middot; Diuretics (e.g., hydrochlorothiazide, furosemide)</p><p>&middot; calcium channel blockers (e.g., verapamil, amlodipine)</p><p>&middot; ACE inhibitors (e.g., captopril, lisinopril)</p><p>&middot; angiotensin II receptor blockers (e.g., valsartan, candesartan)</p><p>&middot; beta blockers (e.g., labetalol, carvedilol)</p><p>&nbsp;</p><p>It may still be all right for you to take the above mentioned medicines and Fancata together and your doctor will be able to decide what is suitable for you.</p><p>&nbsp;</p><p>Taking Fancata with food and drink</p><p>&nbsp;</p><p>Fancata tablets should be taken 30 minutes before breakfast and the evening meal.</p><p>&nbsp;</p><p>Always take your tablets with a drink of water.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>&nbsp;</p><p>Fancata MUST NOT be used during pregnancy.</p><p>&nbsp;</p><p>For breast-feeding mothers use of Fancata is NOT RECOMMENDED.</p><p>&nbsp;</p><p>If you are pregnant, think you may be pregnant or if you are breast-feeding ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p>Driving and using machines</p><p>&nbsp;</p><p>Fancata may cause dizziness. If you feel dizzy after taking Fancata tablets, DO NOT drive and do not use any tools or machines and inform your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot; Always take Fancata exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>&middot; The usual dose is two 50 mg tablets twice a day (morning and evening). This dose does not need to be changed for elderly people. However, your doctor may prescribe a lower dose if you are taking other medicines which may interfere with the effect of Fancata.</p><p>&nbsp;</p><p>&middot; Fancata tablets should be taken 30 minutes before breakfast and the evening meal. Always take your tablets with a drink of water.</p><p>&nbsp;</p><p>Some benefits of taking Fancata may be felt within 4-12 weeks of treatment. Your doctor will assess your progress after 3 months of treatment and may recommend that you discontinue cilostazol if the effect of treatment is insufficient.</p><p>&nbsp;</p><p>Fancata is not suitable for children.</p><p>&nbsp;</p><p>If you take more Fancata than you should</p><p>&nbsp;</p><p>If for any reason you have taken more Fancata tablets than you should, you may have signs and symptoms such as severe headache, diarrhoea, a fall in blood pressure and irregularities of your heartbeat.</p><p>&nbsp;</p><p>If you have taken more tablets than your prescribed dose, contact your doctor or your local hospital immediately. Remember to take the pack with you so that it is clear what medicine you have taken.</p><p>&nbsp;</p><p>If you forget to take Fancata</p><p>&nbsp;</p><p>If you miss a dose, do not worry; wait until the next dose to take your next tablet and then carry on as normal. DO NOT take a double dose to make up for a forgotten tablet.</p><p>&nbsp;</p><p>If you stop taking Fancata</p><p>&nbsp;</p><p>If you stop taking Fancata the pain in your legs may come back or get worse. Therefore, you should only stop taking Fancata if you notice side effects requiring urgent medical attention (see section 4) or if your doctor tells you to.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Fancata can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>If any of the following side effects happen, you may need urgent medical attention. Stop taking Fancata and contact a doctor or go to the nearest hospital immediately.</p><p>&nbsp;</p><p>&middot; stroke</p><p>&nbsp;</p><p>&middot; heart attack</p><p>&nbsp;</p><p>&middot; heart problems which can cause shortness of breath or ankle swelling</p><p>&nbsp;</p><p>&middot; irregular heart beat (new or worsening)</p><p>&nbsp;</p><p>&middot; noticeable bleeding</p><p>&nbsp;</p><p>&middot; easy bruising</p><p>&nbsp;</p><p>&middot; serious illness with blistering of the skin, mouth, eyes and genitals</p><p>&nbsp;</p><p>&middot; yellowing of the skin or whites of the eyes caused by liver or blood problems (jaundice)</p><p>&nbsp;</p><p>You should also tell your doctor immediately if you have a fever or sore throat. You may need to have some blood tests and your doctor will decide on your further treatment.</p><p>&nbsp;</p><p>The following side effects have been reported for Fancata. You should tell your doctor as soon as possible:</p><p>&nbsp;</p><p>Very common side effects (affecting more than 1 in 10 people)</p><p>&nbsp;</p><p>&middot; headache</p><p>&nbsp;</p><p>&middot; abnormal stools</p><p>&nbsp;</p><p>&middot; diarrhoea</p><p>&nbsp;</p><p>Common side effects (affecting less than 1 in 10, but more than 1 in 100 people)</p><p>&nbsp;</p><p>&middot; fast heart beat</p><p>&nbsp;</p><p>&middot; heart pounding (palpitation)</p><p>&nbsp;</p><p>&middot; chest pain</p><p>&nbsp;</p><p>&middot; dizziness</p><p>&nbsp;</p><p>&middot; sore throat</p><p>&nbsp;</p><p>&middot; runny nose (rhinitis)</p><p>&nbsp;</p><p>&middot; abdominal pain</p><p>&nbsp;</p><p>&middot; abdominal discomfort (indigestion)</p><p>&nbsp;</p><p>&middot; feeling or being sick (nausea or vomiting)</p><p>&nbsp;</p><p>&middot; loss of appetite (anorexia)</p><p>&nbsp;</p><p>&middot; excessive burping or wind (flatulence)</p><p>&nbsp;</p><p>&middot; swelling of ankles, feet or face</p><p>&nbsp;</p><p>&middot; rash or changes in appearance of the skin</p><p>&nbsp;</p><p>&middot; itchy skin</p><p>&nbsp;</p><p>&middot; patchy bleeding in the skin</p><p>&nbsp;</p><p>&middot; general weakness</p><p>&nbsp;</p><p>Uncommon side effects (affecting less than 1 in 100, but more than 1 in 1,000 people)</p><p>&nbsp;</p><p>&middot; heart attack</p><p>&nbsp;</p><p>&middot; irregular heart beat (new or worsening)</p><p>&nbsp;</p><p>&middot; heart problems that can cause shortness of breath or ankle swelling</p><p>&nbsp;</p><p>&middot; pneumonia</p><p>&nbsp;</p><p>&middot; cough</p><p>&nbsp;</p><p>&middot; chills</p><p>&nbsp;</p><p>&middot; unexpected bleeding</p><p>&nbsp;</p><p>&middot; tendency to bleed (e.g., of the stomach, eye or muscle, nose bleed and blood in spit or urine)</p><p>&nbsp;</p><p>&middot; decrease in red cells in the blood</p><p>&nbsp;</p><p>&middot; dizziness on standing up</p><p>&nbsp;</p><p>&middot; fainting</p><p>&nbsp;</p><p>&middot; anxiety</p><p>&middot; difficulty sleeping</p><p>&nbsp;</p><p>&middot; unusual dreams</p><p>&nbsp;</p><p>&middot; allergic reaction</p><p>&nbsp;</p><p>&middot; aches and pains</p><p>&nbsp;</p><p>&middot; diabetes and increased blood sugar</p><p>&nbsp;</p><p>&middot; stomach ache (gastritis)</p><p>&nbsp;</p><p>&middot; malaise</p><p>&nbsp;</p><p>There may be a higher risk of bleeding into the eye in people with diabetes.</p><p>&nbsp;</p><p>Rare side effects (affecting less than 1 in 1,000, but more than 1 in 10,000 people):</p><p>&nbsp;</p><p>&middot; tendency to bleed for longer than usual</p><p>&nbsp;</p><p>&middot; increase in the platelets in the blood</p><p>&nbsp;</p><p>&middot; problems with the kidneys</p><p>&nbsp;</p><p>The following side effects have been reported during the use of Fancata but it is not known how frequently they may occur:</p><p>&nbsp;</p><p>&middot; changes in the blood pressure</p><p>&nbsp;</p><p>&middot; decrease in red cells, white cells and platelets in your blood</p><p>&nbsp;</p><p>&middot; difficulty breathing</p><p>&nbsp;</p><p>&middot; difficulty moving</p><p>&nbsp;</p><p>&middot; fever</p><p>&nbsp;</p><p>&middot; hot flushes</p><p>&nbsp;</p><p>&middot; eczema and other skin rashes</p><p>&nbsp;</p><p>&middot; reduced sensation of the skin</p><p>&nbsp;</p><p>&middot; runny or sticky eyes (conjunctivitis)</p><p>&nbsp;</p><p>&middot; ringing in the ears (tinnitus)</p><p>&nbsp;</p><p>&middot; liver problems including hepatitis</p><p>&nbsp;</p><p>&middot; changes in the urine</p><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>&nbsp;</p><p>Do not store above 30&deg;C.</p><p>&nbsp;</p><p>Do not use Fancata after the expiry date which is stated on the carton and blister after &quot;EXP&quot;. The expiry date refers to the last date of the month.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Fancata contains</p><p>&middot; The active substance is cilostazol. One tablet contains 50 mg or 100 mg cilostazol.</p><p>&nbsp;</p><p>&middot; The other ingredients are maize starch, microcrystalline cellulose, carmellose calcium, hypromellose and magnesium stearate.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Fancata 50 mg tablet is a white, off-white, round, flat-faced, debossed “50” on one side.

Fancata 100 mg tablet is a white, off-white, round, flat-faced, debossed “100” on one side.









Your medicine is supplied in packs of 7, 14, 20, 28, 30, 50, 56, 60, 98, 100 tablets packed in PVC/PVDC/Aluminium blisters.

Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder</p><p>&nbsp;</p><p>SPIMACO</p><p>AlQassim pharmaceutical plant</p><p>Saudi Pharmaceutical Industries &amp;</p><p>Medical Appliance Corporation</p><p>P.O. Box 2597 Al-Qassim First Industrial City,</p><p>King AbdulAzziz Road, BURAYDAH 51461,</p><p>Al-Qassim, Saudi Arabia.</p><p>&nbsp;</p><p>Manufacturer</p><p>Adamed Pharma S.A.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July 2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي فانكاتا إلى مجموعة من الأدوية تسمى مثبطات فوسفوداي إيستريز من النوع 3. لديه العديد من التأثيرات التي تشمل توسيع بعض الأوعية الدموية والحد من نشاط التخثر (التجمع) من بعض خلايا الدم تسمى الصفائح الدموية داخل الأوعية الدموية الخاصة بك.</p><p>لقد وصف لك فانكاتا لـ &quot;العرج المتقطع&quot;. العرج المتقطع هو ألم يشبه التشنج في ساقيك عند المشي وهو ناتج عن عدم كفاية إمدادات الدم في ساقيك. يمكن لـ فانكاتا زيادة المسافة التي يمكن المشي بها دون ألم لأنه يحسن الدورة الدموية في ساقيك. ينصح باستخدام سيلوستازول فقط للمرضى الذين لم تتحسن أعراضهم بشكل كاف بعد إجراء تعديلات على نمط الحياة (مثل التوقف عن التدخين وزيادة التمرين) وبعد التدخلات المناسبة الأخرى. من المهم أن تستمر في التعديلات التي أدخلتها على نمط حياتك أثناء تناول سيلوستازول.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول فانكاتا فى الحالات الآتية:</p><p>&bull; إذا كان لديك حساسية زائدة تجاه سيلوستازول أو أى من المكونات الأخرى لـ فانكاتا</p><p>&bull; إذا كنت تعاني من حالة &quot;فشل القلب&quot;</p><p>&nbsp;</p><p>&bull; إذا كنت تعاني من ألم صدري دائم، أو تعرضت &quot;لأزمة قلبية&quot; أو أي عملية جراحية في القلب خلال الأشهر الستة الماضية</p><p>&nbsp;</p><p>&bull; إذا كان لديك الآن أو سبق لك أن عانيت من فقدان الوعي بسبب أمراض القلب، أو أي اضطرابات شديدة في نبضات القلب</p><p>&nbsp;</p><p>&bull; إذا كنت تعلم أن لديك حالة تزيد من خطر النزيف أو الكدمات، مثل:</p><p>&nbsp;</p><p>- قرحة (أو قرح) نشطة في المعدة</p><p>- سكتة دماغية في الأشهر الستة الماضية</p><p>- مشاكل مع عينيك إذا كان لديك مرض السكري</p><p>- إذا لم يتم التحكم في ضغط دمك بشكل جيد</p><p>&nbsp;</p><p>&bull; إذا كنت تتناول كل من حمض أسيتيل الساليسيليك وكلوبيدوجريل، أو أي مزيج من دواءين أو أكثر مما يزيد من خطر النزيف [اسأل طبيبك أو الصيدلي إذا كنت غير متأكد]</p><p>&bull; إذا كان لديك مرض شديد في الكلى أو مرض كبدي متوسط أو شديد</p><p>&bull; إذا كنت حاملا</p><p>&nbsp;</p><p>ينبغى توخى الحذر عند تناول فانكاتا</p><p>قبل تناول فانكاتا تأكد من أن طبيبك يعلم:</p><p>&bull; إذا كان لديك مشكلة قلبية حادة أو أي مشاكل في ضربات قلبك</p><p>&bull; إذا كنت تعاني من مشاكل في ضغط دمك</p><p>خلال العلاج مع فانكاتا تأكد من:</p><p>&bull; إذا كنت بحاجة إلى إجراء جراحة بما في ذلك إزالة الأسنان، أخبر طبيبك أو طبيب الأسنان أنك تتناول فانكاتا</p><p>&bull; إذا كنت تعاني من كدمات أو نزيف سهل، فتوقف عن تناول فانكاتا وأخبر طبيبك</p><p>&nbsp;</p><p>تناول أدوية أخرى</p><p>قبل أن تبدأ في تناول فانكاتا فضلاً أخبر طبيبك المعالج أو الصيدلى إذا كنت تتناول حالياً أو تناولت مؤخراً أى أدوية أخرى. بما فى ذلك الأدوية التى تم الحصول عليها دون وصفة طبية.</p><p>يجب أن تخبر طبيبك على وجه التحديد إذا كنت تتناول بعض الأدوية التي تستخدم عادة لعلاج الحالات المؤلمة و / أو الالتهابية للعضلات أو المفاصل، أو إذا كنت تتناول أدوية للحد من تخثر الدم. هذه الأدوية تشمل:</p><p>&bull; حمض أسيتيل الساليسيليك</p><p>&bull; كلوبيدوجريل</p><p>&bull; الأدوية المضادة للتخثر (على سبيل المثال وارفارين، دابيجاتران، ريفاروكسابان، أبيكسابان أو هيبارين منخفض الوزن الجزيئي)</p><p>إذا كنت تتناول هذه الأدوية مع فانكاتا، فقد يقوم الطبيب بإجراء بعض اختبارات الدم الروتينية.</p><p>&nbsp;</p><p>قد تتداخل بعض الأدوية مع تأثير فانكاتا عندما يتم تناولهم معًا. قد تزيد إما الأعراض الجانبية لـ فانكاتا أو جعل فانكاتا أقل فعالية. قد يفعل فانكاتا الشيء نفسه للأدوية الأخرى. قبل البدء في تناول فانكاتا، يرجى إخبار طبيبك إذا كنت تتناول:</p><p>&nbsp;</p><p>&bull; اريثروميسين، كلاريثروميسين أو ريفامبيسين (المضادات الحيوية)</p><p>&nbsp;</p><p>&bull; كيتوكونازول (لعلاج الالتهابات الفطرية)</p><p>&nbsp;</p><p>&bull; أوميبرازول (لعلاج الحمض الزائد في المعدة)</p><p>&nbsp;</p><p>&bull; ديلتيازيم (لعلاج ارتفاع ضغط الدم أو آلام في الصدر)</p><p>&nbsp;</p><p>&bull; سيسابريد (لعلاج اضطرابات المعدة)</p><p>&nbsp;</p><p>&bull; لوفاستاتين، سيمفاستاتين أو أتورفاستاتين (لعلاج ارتفاع الكوليسترول في الدم)</p><p>&nbsp;</p><p>&bull; هالوفانترين (لعلاج الملاريا)</p><p>&nbsp;</p><p>&bull; بيموزيد (لعلاج الأمراض النفسية)</p><p>&nbsp;</p><p>&bull; مشتقات الشقران (لعلاج الصداع النصفي، على سبيل المثال، إرجوتامين، دايهيدرو إرجوتامين)</p><p>&nbsp;</p><p>&bull; كاربامازبين أو فينيتوين (لعلاج التشنجات)</p><p>&nbsp;</p><p>&bull; نبتة سانت جون (علاج عشبي)</p><p>&nbsp;</p><p>إذا كنت غير متأكد من أن هذا ينطبق على الأدوية الخاصة بك اسأل طبيبك أو الصيدلي.</p><p>&nbsp;</p><p>قبل البدء في تناول فانكاتا، يرجى إبلاغ طبيبك إذا كنت تتناول أدوية لارتفاع ضغط الدم لأن فانكاتا قد يكون له تأثير إضافي على خفض ضغط الدم. إذا انخفض ضغط الدم لديك بشكل أقل من اللازم، فقد يتسبب ذلك في سرعة ضربات القلب. هذه الأدوية تشمل:</p><p>&bull; مدرات البول (على سبيل المثال، هيدروكلوروثيازيد، فوروسيميد)</p><p>&bull; حاصرات قنوات الكالسيوم (على سبيل المثال، فيراباميل، أملوديبين)</p><p>&bull; مثبطات الإنزيم المحول للأنجيوتنسين (مثل كابتوبريل، ليزينوبريل)</p><p>&bull; حاصرات مستقبلات الأنجيوتنسين II (على سبيل المثال، فالسارتان، كانديسارتان)</p><p>&bull; حاصرات بيتا (على سبيل المثال، لابيتالول، كارفيديلول)</p><p>قد يظل من الأفضل لك تناول الأدوية المذكورة أعلاه وفانكاتا معًا وسوف يتمكن طبيبك من تحديد ما يناسبك.</p><p>&nbsp;</p><p>تناول فانكاتا مع الطعام والشراب</p><p>يجب تناول أقراص فانكاتا قبل وجبتي الإفطار والعشاء بـ 30 دقيقة.</p><p>احرص دائمًا على تناول الأقراص باستخدام شراب من الماء.</p><p>&nbsp;</p><p>الحمل والرضاعة</p><p>يجب عدم استخدام فانكاتا أثناء الحمل.</p><p>بالنسبة للأمهات المرضعات، لا ينصح باستخدام فانكاتا.</p><p>إذا كنت حاملاً، تعتقدين أنك قد تكونين حاملاً أو إذا كنت تقومين بالرضاعة الطبيعية فعليك أن تطلبي من طبيبك أو الصيدلي نصيحة قبل تناول أي دواء.</p><p>&nbsp;</p><p>القيادة واستخدام الآلات</p><p>قد يسبب فانكاتا الدوخة. إذا شعرت بالدوار بعد تناول أقراص فانكاتا، فلا تقود ولا تستخدم أي أدوات أو آلات واخبر طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; تناول دائما فانكاتا تماما كما قال لك طبيبك. يجب عليك مراجعة طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p>&bull; الجرعة المعتادة هي 50 ملجم مرتين في اليوم (في الصباح والمساء). هذه الجرعة لا تحتاج إلى تغيير بالنسبة لكبار السن. ومع ذلك، قد يصف لك الطبيب جرعة أقل إذا كنت تتناول أدوية أخرى قد تتداخل مع تأثير فانكاتا.</p><p>&bull; يجب تناول أقراص فانكاتا قبل الإفطار والعشاء بـ 30 دقيقة. احرص دائمًا على تناول الأقراص باستخدام شراب من الماء.</p><p>يمكن الشعور ببعض فوائد تناول فانكاتا خلال 4 إلى 12 أسبوعًا من العلاج. سيقوم طبيبك بتقييم تقدمك بعد 3 أشهر من العلاج وقد يوصي بوقف تناول سيلوستازول إذا كان تأثير العلاج غير كافٍ.</p><p>&nbsp;</p><p>فانكاتا ليس مناسب للأطفال.</p><p>&nbsp;</p><p>إذا كنت تتناول فانكاتا أكثر مما يجب عليك</p><p>&nbsp;</p><p>إذا كنت تناولت فانكاتا أكثر مما يجب لأي سبب من الأسباب، فقد يكون لديك علامات وأعراض مثل الصداع الشديد والإسهال وانخفاض في ضغط الدم وعدم انتظام ضربات القلب.</p><p>&nbsp;</p><p>إذا كنت تتناول أقراصًا أكثر من الجرعة الموصوفة لك، فاتصل بطبيبك أو المستشفى على الفور. تذكر أن تأخذ معك العبوة حتى يتضح الدواء الذي تناولته.</p><p>&nbsp;</p><p>إذا نسيت أن تتناول فانكاتا</p><p>&nbsp;</p><p>إذا نسيت جرعة، فلا تقلق؛ انتظر حتى الجرعة التالية لأخذ قرصك التالي ثم استمر في المعتاد. لا تأخذ جرعة مضاعفة لتعويض القرص المنسي.</p><p>&nbsp;</p><p>إذا توقفت عن تناول فانكاتا</p><p>&nbsp;</p><p>إذا توقفت عن تناول فانكاتا، فقد يعود الألم في ساقيك أو يزداد سوءًا. لذلك، عليك التوقف عن تناول فانكاتا فقط إذا لاحظت أعراض جانبية تتطلب عناية طبية عاجلة (انظر القسم 4) أو إذا أخبرك طبيبك بذلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، قد يسبب فانكاتا أعراضاً جانبية، وإن لم تكن تحدث لكل من يستخدم هذا الدواء.</p><p>إذا حدث أي من الأعراض الجانبية التالية، فقد تحتاج إلى عناية طبية عاجلة. توقف عن تناول فانكاتا واتصل بالطبيب أو اذهب إلى أقرب مستشفى على الفور.</p><p>&bull; سكتة دماغية</p><p>&bull; نوبة قلبية</p><p>&bull; مشاكل في القلب يمكن أن تسبب ضيق التنفس أو تورم الكاحل</p><p>&bull; عدم انتظام ضربات القلب (جديد أو متفاقم)</p><p>&bull; نزيف ملحوظ</p><p>&bull; كدمات سهلة</p><p>&bull; مرض خطير مع تقرحات في الجلد والفم والعينين والأعضاء التناسلية</p><p>&bull; اصفرار الجلد أو بياض العين الناجم عن مشاكل في الكبد أو الدم (اليرقان)</p><p>&nbsp;</p><p>يجب عليك أيضًا إخبار طبيبك على الفور إذا كنت تعاني من الحمى أو التهاب الحلق. قد تحتاج إلى بعض اختبارات الدم وسوف يقرر طبيبك علاجك الإضافي.</p><p>&nbsp;</p><p>تم الإبلاغ عن الأعراض الجانبية التالية لـ فانكاتا. يجب عليك إخبار طبيبك في أقرب وقت ممكن:</p><p>&nbsp;</p><p>أعراض جانبية شائعة جدا (تؤثر على أكثر من 1 من كل 10 أشخاص)</p><p>&bull; صداع</p><p>&bull; براز غير طبيعي</p><p>&bull; إسهال</p><p>&nbsp;</p><p>أعراض جانبية شائعة (التي تؤثر على أقل من 1 من كل 10، ولكن أكثر من 1 من كل 100 شخص)</p><p>&nbsp;</p><p>&bull; نبضات القلب السريعة</p><p>&bull; قصف القلب (خفقان)</p><p>&bull; ألم في الصدر</p><p>&bull; الدوخة</p><p>&bull; إلتهاب الحلق</p><p>&bull; سيلان الأنف (التهاب الأنف)</p><p>&bull; وجع بطن</p><p>&bull; عدم الراحة في البطن (عسر الهضم)</p><p>&bull; الشعور بالغثيان أو الغثيان (الغثيان أو القيء)</p><p>&bull; فقدان الشهية (فقدان الشهية)</p><p>&bull; التجشؤ المفرط أو الرياح (انتفاخ البطن)</p><p>&bull; تورم الكاحلين أو القدمين أو الوجه</p><p>&nbsp;</p><p>&bull; طفح جلدي أو تغيرات في مظهر الجلد</p><p>&bull; حكة في الجلد</p><p>&bull; نزيف مرقع في الجلد</p><p>&bull; ضعف عام</p><p>&nbsp;</p><p>أعراض جانبية غير شائعة (تؤثر على أقل من 1 في 100، ولكن أكثر من 1 من كل 1000 شخص)</p><p>&nbsp;</p><p>&bull; نوبة قلبية</p><p>&nbsp;</p><p>&bull; عدم انتظام ضربات القلب (جديد أو متفاقم)</p><p>&nbsp;</p><p>&bull; مشاكل في القلب يمكن أن تسبب ضيق التنفس أو تورم الكاحل</p><p>&nbsp;</p><p>&bull; الالتهاب الرئوي</p><p>&nbsp;</p><p>&bull; سعال</p><p>&nbsp;</p><p>&bull; قشعريرة</p><p>&nbsp;</p><p>&bull; نزيف غير متوقع</p><p>&nbsp;</p><p>&bull; الميل إلى النزف (على سبيل المثال ، من المعدة والعين أو العضلات ، نزيف الأنف والدم في البصاق أو البول)</p><p>&nbsp;</p><p>&bull; انخفاض في خلايا الدم الحمراء</p><p>&nbsp;</p><p>&bull; الدوخة أثناء الوقوف</p><p>&nbsp;</p><p>&bull; الإغماء</p><p>&nbsp;</p><p>&bull; القلق</p><p>&nbsp;</p><p>&bull; صعوبة النوم</p><p>&nbsp;</p><p>&bull; أحلام غير عادية</p><p>&nbsp;</p><p>&bull; رد فعل تحسسي</p><p>&nbsp;</p><p>&bull; اوجاع والآم</p><p>&nbsp;</p><p>&bull; مرض السكري وزيادة نسبة السكر في الدم</p><p>&nbsp;</p><p>&bull; وجع المعدة (التهاب المعدة)</p><p>&nbsp;</p><p>&bull; توعك</p><p>&nbsp;</p><p>قد يكون هناك خطر أعلى من النزيف في العين لدى مرضى السكري.</p><p>&nbsp;</p><p>الأعراض الجانبية النادرة (التي تؤثر على أقل من 1 في 1000، ولكن أكثر من 1 في 10000 شخص):</p><p>&nbsp;</p><p>&bull; ميل النزف لفترة أطول من المعتاد</p><p>&nbsp;</p><p>&bull; زيادة في الصفائح الدموية في الدم</p><p>&nbsp;</p><p>&bull; مشاكل مع الكلى</p><p>&nbsp;</p><p>تم الإبلاغ عن الأعراض الجانبية التالية أثناء تناول فانكاتا ولكن لا يعرف عدد المرات التي قد تحدث فيها:</p><p>&nbsp;</p><p>&bull; تغيرات في ضغط الدم</p><p>&nbsp;</p><p>&bull; انخفاض في الخلايا الحمراء والخلايا البيضاء والصفائح الدموية في الدم</p><p>&nbsp;</p><p>&bull; صعوبة في التنفس</p><p>&nbsp;</p><p>&bull; صعوبة في التحرك</p><p>&nbsp;</p><p>&bull; حمى</p><p>&nbsp;</p><p>&bull; الهبات الساخنة</p><p>&nbsp;</p><p>&bull; الأكزيما والطفح الجلدي الآخر</p><p>&nbsp;</p><p>&bull; انخفاض الإحساس بالجلد</p><p>&nbsp;</p><p>&bull; سيلان أو عيون لزجة (التهاب الملتحمة)</p><p>&nbsp;</p><p>&bull; رنين في الأذنين (طنين)</p><p>&nbsp;</p><p>&bull; مشاكل الكبد بما في ذلك التهاب الكبد</p><p>&nbsp;</p><p>&bull; تغيرات في البول</p><p>&nbsp;</p><p>إذا لاحظت أن أياً من هذه الأعراض الجانبية أصبح جسيماً، أو إذا لاحظت ظهور أى أعراض جانبية لم ترد فى هذه النشرة فإنه يرجى أن تخبر طبيبك المعالج أو الصيدلى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيداً عن متناول ونظر الأطفال.</p><p>لا يحفظ في درجة حرارة أعلي من 30 درجة مئوية.</p><p>لا تستخدم فانكاتا بعد انتهاء تاريخ الصلاحية المدون على العبوة. تاريخ الانتهاء هو آخر يوم فى ذلك الشهر.</p><p>يجب عدم التخلص من الأدوية عبر مياه الصرف الصحى أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. لأن هذه الاعتبارات ستعمل على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>علام يحتوى فانكاتا:</p><p>المادة الفعالة هى سيلوستازول. يحتوي كل قرص على 50 ملجم أو 100 ملجم سيلوستازول.</p><p>المكونات الأخرى هى:</p><p>نشاء ذرة، مايكروكريستال سيليلوز، كارميلوز كالسيوم، هيبروميلوز و ستيرات المغنيسيوم.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>قرص فانكاتا 50 ملجم هو قرص أبيض، أبيض فاتح، مستدير، مسطح الوجه، مطبوع عليه &quot;50&quot; على جانب واحد.</p><p>قرص فانكاتا 100 ملجم هو قرص أبيض، أبيض فاتح، مستدير، مسطح الوجه، مطبوع عليه &quot;100&quot; على جانب واحد.</p><p>يتم توفير الدواء الخاص بك في عبوات من 7، 14، 20، 28، 30، 50، 56، 60، 98، 100 قرص في شرائط PVC / PVDC / ألومنيوم.</p><p>قد لا يتم تسويق جميع أحجام العبوات</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك الحقوق التسويقية</p><p>الدوائية</p><p>مصنع الأدوية بالقصيم</p><p>الشركة السعودية للصناعات الدوائية والمستلزمات الطبية.</p><p>صندوق بريدي 2597 المنطقة الصناعية الأولي بالقصيم،</p><p>طريق الملك عبد العزيز، بريدة 51461،</p><p>القصيم، المملكة العربية السعودية</p><p>&nbsp;</p><p>المصنع</p><p>أداميد فارما إس إيه</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             يوليو 2019.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fancata 50 mg tablets 

Fancata 100 mg tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One tablet contains 50 mg or 100 mg of cilostazol. 

For a full list of excipients, see section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fancata&nbsp;is indicated for the improvement of the maximal and pain-free walking distances in patients with intermittent claudication, who do not have rest pain and who do not have evidence of peripheral tissue necrosis (peripheral arterial disease Fontaine stage II).&nbsp;</p><p>Fancata&nbsp;is for second-line use, in patients in whom lifestyle modifications (including stopping smoking and [supervised] exercise programs) and other appropriate interventions have failed to sufficiently improve their intermittent claudication symptoms.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology&nbsp;</p><p>The recommended dosage of cilostazol is 100 mg twice a day. Cilostazol should be taken 30 minutes before breakfast and the evening meal. Taking cilostazol with food has been shown to increase the maximum plasma concentrations (Cmax) of cilostazol, which may be associated with an increased frequency of adverse reactions.&nbsp;</p><p>Cilostazol should be initiated by physicians experienced in the management of intermittent claudication (see also section 4.4).&nbsp;</p><p>The physician should reassess the patient after 3 months of treatment with a view to discontinuing cilostazol where an inadequate effect is&nbsp;observed&nbsp;or symptoms have not been improved.&nbsp;</p><p>Patients receiving treatment with cilostazol should continue with their life-style modifications (smoking cessation and exercise), and pharmacological interventions (such as lipid lowering and antiplatelet treatment) to reduce the risk of cardiovascular events. Cilostazol is not a substitute for such treatments.&nbsp;</p><p>Reduction of the dose to 50 mg twice daily is recommended in patients receiving medicines that strongly inhibit CYP3A4, for example some macrolides, azole antifungals, protease&nbsp;inhibitors, or medicines that strongly inhibit CYP2C19, for example omeprazole (see sections 4.4 and 4.5).&nbsp;</p><p>The elderly&nbsp;</p><p>There are no special dosage requirements for the elderly.&nbsp;</p><p>Paediatric population&nbsp;</p><p>Safety and efficacy in children have not been established.&nbsp;</p><p>Renal impairment&nbsp;</p><p>No dose adjustment is necessary in patients with a creatinine clearance of &gt; 25 ml/min. Cilostazol is contraindicated in patients with a creatinine clearance of &le; 25 ml/min.&nbsp;</p><p>Hepatic impairment&nbsp;</p><p>No dosage adjustment is necessary in patients with mild hepatic disease. There are no data in patients with moderate or severe hepatic impairment. Since cilostazol is extensively metabolised by hepatic enzymes, it is contraindicated in patients with moderate or severe hepatic impairment.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Known hypersensitivity to cilostazol or to any of the excipients 

• Severe renal impairment: creatinine clearance of ≤ 25 ml/min 

• Moderate or severe hepatic impairment 

• Congestive heart failure 

• Pregnancy 

• Patients with any known predisposition to bleeding (e.g. active peptic ulceration, recent [within six months] haemorrhagic stroke, proliferative diabetic retinopathy, poorly controlled hypertension) 

• Patients with any history of ventricular tachycardia, ventricular fibrillation or multifocal ventricular ectopics, whether or not adequately treated, and in patients with prolongation of the QTc interval 

• Patients with a history of severe tachyarrhythmia 

• Patients treated concomitantly with two or more additional antiplatelet or anticoagulant agents (e.g. acetylsalicylic acid, clopidogrel, heparin, warfarin, acenocoumarol, dabigatran, rivaroxaban or apixaban) 

• Patients with unstable angina pectoris, myocardial infarction within the last 6 months, or a coronary intervention in the last 6 months. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The suitability of treatment with cilostazol should be carefully considered alongside other treatment options such as revascularisation.&nbsp;</p><p>Based on its mechanism of action, cilostazol may induce tachycardia, palpitation, tachyarrhythmia and/or hypotension. The increase in heart rate associated with cilostazol is approximately 5 to 7 bpm; in patients at risk this consequently may induce angina pectoris.&nbsp;</p><p>Patients who may be at increased risk for serious cardiac adverse events&nbsp;as a result of&nbsp;increased heart rate, e.g. patients with stable coronary disease, should be closely monitored during treatment with cilostazol, while the use of cilostazol in patients with unstable angina pectoris, or myocardial infarction/coronary intervention within the last 6 months, or a history of severe tachyarrhythmia is contraindicated (see section 4.3).&nbsp;</p><p>Caution should be exercised when prescribing cilostazol for patients with atrial or ventricular ectopy and patients with atrial fibrillation or flutter.&nbsp;</p><p>Patients should be warned to report any episode of bleeding or easy bruising whilst on therapy. In case of retinal bleeding administration of cilostazol should be stopped. Refer to sections 4.3 and 4.5 for further information on bleeding risks.&nbsp;</p><p>Due to cilostazol&#39;s platelet aggregation inhibitory effect it is possible that an increased bleeding risk occurs in combination with surgery (including minor invasive measurements like tooth extraction). If a patient is to undergo elective surgery and antiplatelet effect is not necessary, cilostazol should be stopped 5 days prior to surgery.&nbsp;</p><p>There have been rare or very rare reports of haematological abnormalities including thrombocytopenia,&nbsp;leucopenia, agranulocytosis, pancytopenia and aplastic anaemia (see section 4.8). Most patients recovered on discontinuation of cilostazol. However, some cases of pancytopenia and aplastic anaemia had a fatal outcome.&nbsp;</p><p>In addition to reporting episodes of bleeding and easy bruising, patients should be warned to promptly report any other signs which might also suggest the early development of blood dyscrasia such as pyrexia and sore throat. A full blood count should be performed if infection is suspected or there is any other clinical evidence of blood dyscrasia. Cilostazol should be discontinued promptly if there is clinical or laboratory evidence of haematological abnormalities.&nbsp;</p><p>In the case of patients receiving strong inhibitors for CYP3A4 or CYP2C19, plasma levels of cilostazol were shown to be increased. In such cases, a cilostazol dosage of 50 mg twice daily is recommended (see section 4.5 for further information).&nbsp;</p><p>Caution is needed when co-administering cilostazol with any other agent which has the potential to reduce blood pressure due to the possibility that there may be an additive hypotensive effect with a reflex tachycardia. Refer also to section 4.8.&nbsp;</p><p>Caution should be exercised when co-administering cilostazol with any other agents that inhibit platelet aggregation. Refer to sections 4.3 and 4.5.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Inhibitors of platelet aggregation&nbsp;</p><p>Cilostazol is a PDE III inhibitor with antiplatelet activity. In a clinical study in healthy subjects, cilostazol given 150mg&nbsp;b.i.d. for five days did not result in prolongation of bleeding time.&nbsp;</p><p>Acetylsalicylic Acid (ASA)&nbsp;</p><p>Short term (&le;4 days) co-administration of ASA with cilostazol suggested a 23-25% increase in inhibition of ADP-induced ex&nbsp;vivoplatelet&nbsp;aggregation when compared to ASA alone.&nbsp;</p><p>There were no apparent trends toward a greater frequency of haemorrhagic adverse effects in patients taking cilostazol and ASA compared to patients taking placebo and equivalent doses of ASA.&nbsp;</p><p>Clopidogrel&nbsp;and other antiplatelet drugs&nbsp;</p><p>Concomitant administration of cilostazol and&nbsp;clopidogrel&nbsp;did not have any effect on platelet count, prothrombin time (PT) or activated partial thromboplastin time (aPTT). All healthy subjects in the study had a prolongation of bleeding time on&nbsp;clopidogrel&nbsp;alone and concomitant administration with cilostazol did not result in a significant additional effect on bleeding time. Caution is advised when co-administering cilostazol with any drug that inhibits platelet aggregation. Consideration should be given to monitoring the bleeding time at intervals. Cilostazol treatment is contraindicated in patients receiving two or more additional antiplatelet/anticoagulant agents (see section 4.3).&nbsp;</p><p>A higher rate of haemorrhage was observed with the concomitant use of&nbsp;clopidogrel, ASA and cilostazol in the CASTLE trial.&nbsp;</p><p>Oral Anticoagulants like warfarin&nbsp;</p><p>In a single-dose clinical study, no inhibition of the metabolism of warfarin or an effect on the coagulation parameters (PT,&nbsp;aPTT, bleeding time) was observed. However, caution is advised in patients receiving both cilostazol and any anticoagulant agent, and frequent monitoring is required to reduce the possibility of bleeding.&nbsp;</p><p>Cilostazol treatment is contraindicated in patients receiving two or more additional antiplatelet/anticoagulant agents (see section 4.3).&nbsp;</p><p>Cytochrome P-450 (CYP) enzyme inhibitors&nbsp;</p><p>Cilostazol is extensively metabolised by CYP enzymes, particularly CYP3A4 and CYP2C19 and to a lesser extent CYP1A2. The&nbsp;dehydro&nbsp;metabolite, which has 4-7 times the potency of cilostazol in inhibiting platelet aggregation, appears to be formed primarily via CYP3A4. The 4`-trans-hydroxy metabolite, with potency one-fifth that of cilostazol, appears to be formed primarily via CYP2C19. Therefore, drugs inhibiting CYP3A4 (e.g., some macrolides, azole antifungals, protease inhibitors) or CYP2C19 (like proton pump inhibitors, PPIs) increase the total pharmacological activity and could have the potential to enhance the undesirable effects of cilostazol. Consequently, for patients concomitantly taking strong CYP3A4 or CYP2C19 inhibitors the recommended dose is 50 mg twice daily (see section 4.2).&nbsp;</p><p>Administration of cilostazol with erythromycin (an inhibitor of CYP3A4) resulted in an increase in the AUC of cilostazol by 72%, accompanied by a 6% increase in AUC of the&nbsp;dehydro&nbsp;metabolite and a 119% increase in AUC of the 4`-trans-hydroxy metabolite.&nbsp;</p><p>Based on AUC, the overall pharmacological activity of cilostazol increases 34% when co-administered with erythromycin. Based on these data, the recommended dose of cilostazol is 50 mg bid in the presence of erythromycin and similar agents (e.g., clarithromycin).&nbsp;</p><p>Co-administration of ketoconazole (an inhibitor of CYP3A4 with cilostazol resulted in a 117% increase in the AUC of cilostazol, accompanied by a 15% decrease in the AUC of the&nbsp;dehydro&nbsp;metabolite and&nbsp;a&nbsp;87% increase in the AUC of the 4`-trans-hydroxy metabolite. Based on AUC, the overall pharmacological activity of cilostazol increases 35% when co-administered with ketoconazole. Based on these data, the recommended dose of cilostazol is 50 mg bid in the presence of ketoconazole and similar agents (e.g., itraconazole).&nbsp;</p><p>Administration of cilostazol with diltiazem (a weak inhibitor of CYP3A4) resulted in an increase in the AUC of cilostazol of 44%, accompanied by a 4% increase in AUC of the&nbsp;dehydro&nbsp;metabolite and a 43% increase in the AUC of the 4`-trans-hydroxy metabolite.&nbsp;</p><p>Based on AUC, overall pharmacological activity of cilostazol increases 19 % when co-administered with diltiazem. Based on these data, no dose adjustment is necessary.&nbsp;</p><p>Administration of a single dose of 100 mg cilostazol with 240 ml grapefruit juice (an inhibitor of intestinal CYP3A4) did not have a notable effect on the pharmacokinetics of cilostazol. Based on these data, no dose adjustment is necessary. A clinically relevant effect on cilostazol is still possible at higher quantities of grapefruit juice.&nbsp;</p><p>Administration of cilostazol with omeprazole (an inhibitor of CYP2C19) increased the AUC of cilostazol by 22%, accompanied by a 68% increase in the AUC of the&nbsp;dehydro&nbsp;metabolite and a decrease of 36% in the AUC of the 4`-trans hydroxy metabolite. Based on AUC, the overall pharmacological activity increases by 47% when co-administered with omeprazole. Based on these data, the recommended dose of cilostazol is 50 mg bid in the presence of omeprazole.&nbsp;</p><p>Cytochrome P-450 enzyme substrates&nbsp;</p><p>Cilostazol has been shown to increase the AUC of lovastatin (sensitive substrate for CYP3A4) and its &beta;-hydroxy acid by 70%. Caution is advised when cilostazol is co-administered with CYP3A4 substrates with a narrow therapeutic index (e.g.,&nbsp;cisapride, halofantrine, pimozide, ergot derivates). Caution is advised in case of co-administration with statins metabolised by CYP3A4, for example simvastatin, atorvastatin and lovastatin.&nbsp;</p><p>Cytochrome P-450 enzyme inducers&nbsp;</p><p>The effect of CYP3A4 and CYP2C19 inducers (such as carbamazepine, phenytoin, rifampicin and St. John&#39;s wort) on cilostazol pharmacokinetics has not been evaluated. The antiplatelet effect may theoretically be altered and should be carefully monitored when cilostazol is co-administered with CYP3A4 and CYP2C19 inducers.&nbsp;</p><p>In clinical trials, smoking (which induces CYP1A2) decreased cilostazol plasma concentrations by 18%.&nbsp;</p><p>Other potential interactions&nbsp;</p><p>Caution is needed when co-administering cilostazol with any other agent which has the potential to reduce blood pressure due to the possibility that there may be an additive hypotensive effect with a reflex tachycardia.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy&nbsp;</p><p>There are no adequate data in the use of cilostazol in pregnant women. Studies in animals have shown reproductive toxicity (see Section 5.3). The potential risk for humans is unknown.&nbsp;Fancata&nbsp;must not be used during pregnancy (see section 4.3).&nbsp;</p><p>Lactation&nbsp;</p><p>The transfer of cilostazol to breast milk has been reported in animal studies. The excretion of cilostazol in human milk is unknown. Due to the potential harmful effect in the&nbsp;newborn&nbsp;child breast fed by a treated mother, the use of&nbsp;Fancata&nbsp;is not recommended during breast feeding.&nbsp;</p><p>Fertility&nbsp;</p><p>Cilostazol reversibly impaired fertility of female mice but not in other animal species (see section 5.3). The clinical significance is unknown.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cilostazol may cause dizziness and patients should be warned to exercise caution before they drive or operate machinery.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported adverse reactions in clinical trials were headache (in &gt; 30%), diarrhoea and abnormal stools (in &gt; 15% each). These reactions were usually of mild to moderate intensity and were sometimes alleviated by reducing the dose.&nbsp;</p><p>Adverse reactions reported in clinical trials and in the post-marketing period are included in the table below.&nbsp;</p><table border="1"><tbody><tr><td><p>The frequencies correspond with:&nbsp;</p></td><td><p>Very common&nbsp;</p><p>Common&nbsp;</p><p>Uncommon&nbsp;</p><p>Rare&nbsp;</p><p>Very rare&nbsp;</p></td><td><p>(&ge;1/10)&nbsp;</p><p>(&ge;1/100 to &lt;1/10)&nbsp;</p><p>(&ge;1/1,000 to &lt;1/100)&nbsp;</p><p>(&ge;1/10,000 to &lt;1/1000)&nbsp;</p><p>(&lt;1/10,000), not known (cannot be estimated from the available data)&nbsp;</p></td></tr></tbody></table><p>The frequencies of reactions observed in the post-marketing period are considered unknown (cannot be estimated from the available data).&nbsp;</p><table border="1"><tbody><tr><td><p>Blood and the lymphatic system disorders&nbsp;</p></td><td><p>Common&nbsp;</p><p>Uncommon&nbsp;</p><p>Unknown&nbsp;</p></td><td><p>Ecchymosis&nbsp;</p><p>Anaemia&nbsp;</p><p>Rare&nbsp;</p><p>Bleeding tendency thrombocytopenia,&nbsp;granulocytopenia, agranulocytosis, leukopenia, pancytopenia, aplastic anaemia&nbsp;</p></td><td><p> &nbsp;</p><p> &nbsp;</p><p>Bleeding time prolonged,&nbsp;thrombocythaemia&nbsp;</p></td></tr><tr><td><p>Immune system disorders&nbsp;</p></td><td><p>Uncommon&nbsp;</p></td><td><p>Allergic reaction&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Metabolism and nutrition disorders&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Common&nbsp;</p><p>Uncommon&nbsp;</p></td><td><p>Oedema (peripheral, face), anorexia&nbsp;</p><p>Hyperglycaemia, Diabetes mellitus&nbsp;</p></td></tr><tr><td><p>Psychiatric disorders&nbsp;</p></td><td><p>Uncommon&nbsp;</p></td><td><p>Anxiety&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Nervous system disorders&nbsp;</p></td><td><p>Very common&nbsp;</p><p>Common&nbsp;</p></td><td><p>Headache&nbsp;</p><p>Dizziness&nbsp;</p><p>Uncommon&nbsp;</p><p>Unknown&nbsp;</p></td><td><p> &nbsp;</p><p> &nbsp;</p><p>Insomnia, abnormal dreams&nbsp;</p><p>Paresis,&nbsp;hypoaesthesia&nbsp;</p></td></tr><tr><td><p>Eye disorders&nbsp;</p></td><td><p>Unknown&nbsp;</p></td><td><p>Conjunctivitis&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Ear and labyrinth disorders&nbsp;</p></td><td><p>Unknown&nbsp;</p></td><td><p>Tinnitus&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Cardiac disorders&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Common&nbsp;</p><p> &nbsp;</p><p>Uncommon&nbsp;</p></td><td><p>Palpitation,tachycardia, angina pectoris, arrhythmia, ventricular&nbsp;extrasystoles&nbsp;</p><p>Myocardial infarction, atrial fibrillation, congestive heart&nbsp;failure, supraventricular tachycardia, ventricular tachycardia, syncope&nbsp;</p></td></tr><tr><td><p>Vascular disorders&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Uncommon&nbsp;</p><p> &nbsp;</p><p>Unknown&nbsp;</p></td><td><p>Eye haemorrhage, epistaxis, gastrointestinal haemorrhage, haemorrhage unspecified, orthostatic hypotension&nbsp;</p><p>Hot flushes,&nbsp;hypertension,hypotension, cerebral haemorrhage, pulmonary haemorrhage, muscle haemorrhage, respiratory tract haemorrhage, subcutaneous haemorrhage&nbsp;</p></td></tr><tr><td><p>Respiratory, thoracic and mediastinal disorders&nbsp;</p></td><td><p> &nbsp;</p><p> &nbsp;</p><p>Unknown&nbsp;</p></td><td><p>Common&nbsp;</p><p>Uncommon&nbsp;</p><p>Interstitial pneumonia&nbsp;</p></td><td><p>Rhinitis, pharyngitis&nbsp;</p><p>Dyspnoea, pneumonia, cough&nbsp;</p></td></tr><tr><td><p>Gastrointestinal disorders&nbsp;</p></td><td><p> &nbsp;</p><p> &nbsp;</p><p>Uncommon&nbsp;</p></td><td><p>Very common&nbsp;</p><p>Common&nbsp;</p><p>Gastritis&nbsp;</p></td><td><p>Diarrhoea, abnormal faeces&nbsp;</p><p>Nausea and vomiting, dyspepsia, flatulence, abdominal pain&nbsp;</p></td></tr><tr><td><p>Hepato-biliary disorders&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Unknown&nbsp;</p></td><td><p>Hepatitis, hepatic function abnormal, jaundice&nbsp;</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Common&nbsp;</p><p>Unknown&nbsp;</p></td><td><p>Rash, pruritus&nbsp;</p><p>Eczema, skin eruptions, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria&nbsp;</p></td></tr><tr><td><p>Musculoskeletal, connective tissue and bone disorders&nbsp;</p></td><td><p>Uncommon&nbsp;</p></td><td><p>Myalgia&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Renal and urinary disorders&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Rare&nbsp;</p><p>Unknown&nbsp;</p></td><td><p>Renal failure, renal impairment&nbsp;</p><p>Haematuria, pollakiuria&nbsp;</p></td></tr><tr><td><p>General disorders and administration site conditions&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Common&nbsp;</p><p>Uncommon&nbsp;</p><p>Unknown&nbsp;</p></td><td><p>Chest pain, asthenia&nbsp;</p><p>Chills, malaise&nbsp;</p><p>Pyrexia, pain&nbsp;</p></td></tr><tr><td><p>Investigations&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>Unknown&nbsp;</p></td><td><p>Uric acid level increased, blood urea increased, blood creatinine increased&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>An increase in the frequency of palpitation and peripheral oedema was observed when cilostazol was combined with other vasodilators that cause reflex tachycardia e.g. dihydropyridine calcium channel blockers.&nbsp;</p><p>The only adverse event resulting in discontinuation of therapy in &ge; 3% of patients treated with cilostazol was headache. Other frequent causes of discontinuation included palpitation and diarrhoea (both 1.1%).&nbsp;</p><p>Cilostazol per se may carry an increased risk of bleeding and this risk may be potentiated by co-administration with any other agent with such potential.&nbsp;</p><p>The risk of intraocular bleeding may be higher in patients with diabetes.&nbsp;</p><p>An increase in the frequency of diarrhoea and palpitation has been found in patients older than 70 years.&nbsp;</p><p><img alt="Text Box" src="data:image/png;base64,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" />&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Information on acute overdose in humans is limited. The signs and symptoms can be anticipated to be severe headache, diarrhoea, tachycardia and possibly cardiac arrhythmias.&nbsp;</p><p>Patients should be observed and given supportive treatment. The stomach should be emptied by induced vomiting or gastric lavage, as appropriate.&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antithrombotic agents, platelet aggregation inhibitor excl. heparin.&nbsp;</p><p>ATC code: B01A C&nbsp;</p><p>From data generated in nine placebo-controlled studies (where 1,634 patients were exposed to cilostazol), it has been demonstrated that cilostazol improves exercise capacity as judged by changes in Absolute Claudication Distance (ACD, or maximal walking distance) and Initial Claudication Distance (ICD, or pain-free walking distance) upon treadmill testing. Following 24 weeks treatment, cilostazol 100 mg&nbsp;b.i.d. increases in mean ACD ranged from 60.4 - 129.1 metres, whilst mean ICD increases ranged from 47.3 - 93.6 metres.&nbsp;</p><p>A meta-analysis based on weighted mean differences across the nine studies indicated that there was a significant absolute overall post-baseline improvement of 42 m in maximal walking distance (ACD) for cilostazol 100 mg&nbsp;b.i.d. over the improvement seen under placebo. This corresponds to a relative improvement of 100% over placebo. This effect appeared lower in diabetics than in non-diabetics.&nbsp;</p><p>Animal studies have shown cilostazol to have vasodilator effects and this has been demonstrated in small studies in man where ankle blood flow was measured by strain gauge plethysmography. Cilostazol also inhibits smooth muscle cell proliferation in rat and human smooth muscle cells in vitro, and&nbsp;inhibits the platelet release reaction of platelet-derived growth factor and PF-4 in human platelets.&nbsp;</p><p>Studies in animals and in man (in vivo and ex vivo) have shown that cilostazol causes reversible inhibition of platelet aggregation. The inhibition is effective against a range of&nbsp;aggregants&nbsp;(including shear stress, arachidonic acid, collagen, ADP and adrenaline); in man the inhibition lasts for up to 12 hours, and on cessation of administration of cilostazol recovery of aggregation occurred within 48-96 hours, without rebound hyperaggregability. Effects on circulating plasma lipids have been examined in patients taking&nbsp;Fancata. After 12&nbsp;weeks, as compared to placebo,&nbsp;Fancata&nbsp;100 mg&nbsp;b.i.d. produced a reduction in triglycerides of 0.33 mmol/l (15%) and an increase in HDL-cholesterol of 0.10 mmol/l (10%).&nbsp;</p><p>A randomized, double-blind, placebo-controlled Phase IV study was conducted to assess the long-term effects of cilostazol, with focus on mortality and safety. In total, 1,439 patients with intermittent claudication and no heart failure have been treated with cilostazol or placebo for up to three years. With respect to mortality, the observed 36-month Kaplan-Meier event rate for deaths on study drug with a median time on study drug of 18 months was 5.6% (95%CI of 2.8 to 8.4%) on cilostazol and 6.8% (95% CI of 1.9 to 11.5%) on placebo. Long-term treatment with cilostazol did not raise safety concerns.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following multiple doses of cilostazol 100 mg twice daily in patients with peripheral vascular disease, steady state is achieved within 4 days.&nbsp;</p><p>The&nbsp;Cmax of cilostazol and its primary circulating metabolites increase less than proportionally with increasing doses. However, the AUC for cilostazol and its metabolites increase approximately proportionately with dose.&nbsp;</p><p>The apparent elimination half-life of cilostazol is 10.5 hours. There are two major metabolites, a dehydro-cilostazol and a 4&#39;-trans-hydroxy cilostazol, both of which have similar apparent half-lives. The&nbsp;dehydro&nbsp;metabolite is 4-7 times as active a platelet antiaggregant as the parent compound and the 4&#39;-trans-hydroxy metabolite is one fifth as active. Plasma concentrations (as measured by AUC) of the&nbsp;dehydro&nbsp;and 4`-trans-hydroxy metabolites are ~41% and ~12% of cilostazol concentrations.&nbsp;</p><p>Cilostazol is eliminated predominantly by metabolism and subsequent urinary excretion of metabolites. The primary isoenzymes involved in its metabolism are cytochrome P-450 CYP3A4, to a lesser extent, CYP2C19, and to an even lesser extent CYP1A2.&nbsp;</p><p>The primary route of elimination is urinary (74%) with the remainder excreted in the faeces. No measurable amount of unchanged cilostazol is excreted in the urine, and less than 2% of the dose is excreted as the dehydro-cilostazol metabolite. Approximately 30% of the dose is excreted in the urine as the 4&#39;-trans-hydroxy metabolite. The remainder is excreted as metabolites, none of which exceed 5% of the total excreted.&nbsp;</p><p>Cilostazol is 95-98% protein bound, predominantly to albumin. The&nbsp;dehydro&nbsp;metabolite and 4&#39;-trans-hydroxy metabolite are 97.4% and 66% protein bound respectively.&nbsp;</p><p>There is no evidence that cilostazol induces hepatic microsomal enzymes.&nbsp;</p><p>The pharmacokinetics of cilostazol and its metabolites were not significantly affected by age or gender in healthy subjects aged between 50-80 years.&nbsp;</p><p>In subjects with severe renal impairment, the free fraction of cilostazol was 27% higher and both&nbsp;Cmax and AUC were 29% and 39% lower respectively than in subjects with normal renal function. The&nbsp;Cmax and AUC of the&nbsp;dehydro&nbsp;metabolite were 41% and 47% lower respectively in the severely renally impaired subjects compared to subjects with normal renal function. The&nbsp;Cmax and AUC of 4&#39;-trans-hydroxy cilostazol were 173% and 209% greater in subjects with severe renal impairment. The medicine must not be administered to patients with a creatinine clearance &lt;25ml/min (see section 4.3).&nbsp;</p><p>There are no data in patients with moderate to severe hepatic impairment and since cilostazol is extensively metabolised by hepatic enzymes, the medicine must not be used in such patients (see section 4.3).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cilostazol and several of its metabolites are phosphodiesterase III inhibitors which suppress cyclic AMP degradation, resulting in increased cAMP in a variety of tissues including platelets and blood vessels. As with other positive inotropic and vasodilator agents, cilostazol produced cardiovascular lesions in dogs. Such lesions were not seen in rats or monkeys and are considered species specific. Investigation of QTc in dogs and monkeys showed no prolongation after administration of cilostazol or its metabolites.&nbsp;</p><p>Mutagenicity studies were negative in bacterial gene mutation, bacterial DNA repair, mammalian cell gene mutation and mouse in vivo bone marrow chromosomal aberrations. In in vitro tests on Chinese ovary hamster cells cilostazol produced a weak but significant increase in chromosome aberration frequency. No unusual neoplastic outcomes were observed in two-year carcinogenicity studies in rats at oral (dietary) doses up to 500 mg/kg/day, and in mice at doses up to 1000 mg/kg/day.&nbsp;</p><p>In rats dosed during pregnancy, foetal weights were decreased. In addition, an increase in foetuses with external, visceral and skeletal abnormalities was noted at high dose levels. At lower dose levels, retardations of ossification were observed. Exposure in late pregnancy resulted in an increased frequency of stillbirths and lower offspring weights. An increased frequency of retardation of ossification of the sternum was observed in rabbits.&nbsp;</p><p>Cilostazol inhibited mouse oocyte maturation in vitro, and in female mice caused a reversible impairment of fertility. No effect on fertility was observed in rats or in non-human primates. The relevance to humans is unknown.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Maize&nbsp;starch, microcrystalline cellulose,&nbsp;carmellose&nbsp;calcium,&nbsp;hypromellose&nbsp;and magnesium stearate.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the reach and sight of children.&nbsp;</p><p>Do not store above 30&deg;C.&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Your medicine is supplied in packs of 7, 14, 20, 28, 30, 50, 56, 60, 98, 100 tablets packed in PVC/PVDC/Aluminium blisters.&nbsp;</p><p>Not all pack sizes may be marketed.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder 

SPIMACO 

AlQassim pharmaceutical plant 

Saudi Pharmaceutical Industries & 

Medical Appliance Corporation 

P.O. Box 2597 Al-Qassim First Industrial City,  

King AbdulAzziz Road, BURAYDAH 51461,  

Al-Qassim, Saudi Arabia.  

Manufacturer 

Adamed Pharma S.A. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2019. 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>